FDA selects new members for the Patient Engagement Collaborative

Today, the U.S. Food and Drug Administration (FDA), in collaboration with the Clinical Trials Transformation Initiative (CTTI), selected eight new members to participate in the Patient Engagement Collaborative (PEC). The eight new members are: Carol Abraham Julie Breneiser Sneha Dave Maria De Leon Sharon Lagas John Linnell James Pantelas Traceann Rose The members were selected from more than 100 applications received in response to a Federal Register notice. The new members of the PEC include patients who have personal disease experience, caregivers who have personal experience supporting someone with a health condition and members from patient groups who have direct disease experience. The selection committee, which included patient advocates, FDA staff, CTTI staff and several outgoing PEC members, worked to identify individuals with diverse perspectives and experiences who could meaningfully contribute and express the patient voice. Special thanks to the members moving on from the PEC for their service over the past several years: Dawn Aldrich Christine Brown Jeffrey Goldstein Melissa Hogan Nancy Lenfestey Stephanie Monroe Theresa Strong Dave White The PEC, established in 2018, is a group of patient organizations and individual members who discuss ways to enhance patient engagement. CTTI and the FDA collaborate to involve members with a variety of perspectives including patients, caregivers and members from diverse patient organizations. The PEC is run by the FDA's Patient Affairs office, which is dedicated to providing an inviting, welcoming and meaningful experience for patient communities to engage with the FDA. Contact PatientAffairs@fda.hhs.gov with questions.   Manage Subscriptions  |  Unsubscribe All  |  Help This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA